XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.1

Segments (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below summarizes the significant expense categories regularly reviewed by the Company’s president and chief executive officer, who is the Company’s chief operating decision maker (“CODM”), for the three months ended March 31, 2025 and 2024:

									Three Months Ended March 31,
															2025						2024
Research and development expenses:
Clinical trial expenses:
IT-01 Study (Phase 1/2 Metastatic Cancers)															$	—					$	53
INVINCIBLE-2 Study (Phase 2 Breast)															—						103
INVINCIBLE-3 Study (Phase 3 Sarcoma)															1,596						1,419
INVINCIBLE-4 Study (Phase 2 Breast)															63						—
Clinical trial expenses															1,659						1,575
Contract manufacturing															24						214
Salaries and benefits related															329						394
Consulting & Other(a)															17						66
Stock-based compensation															160						566
Research and development expenses															2,189						2,815
General and administrative expenses:
Salaries and benefits related															230						324
Legal fees															167						257
Audit fees															77						115
Consulting															196						173
Insurance															157						286
Other(b)															103						184
Stock-based compensation															275						589
General and administrative expenses															1,205						1,928
Loss from operations															(3,394)						(4,743)
Other segment items(c)															47						140
Net loss															$	(3,347)					$	(4,603)

(a)Consulting & Other includes research and development consulting costs and travel-related costs.

(b)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs.

(c)Other segment items include interest income, interest expense, and foreign exchange gains and losses.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration